DBV Technologies | DBVT - Interest Expense On Debt


DBV Technologies reported $461K in Interest Expense on Debt for its fiscal quarter ending in March of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amarin USD 3K 5K Dec/2024
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
DBV Technologies USD 461K 323.71K Mar/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
Galectin Therapeutics USD 1.27M 220K Jun/2024
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Incyte USD 582K 10K Dec/2025
Insmed USD 20.6M 217K Dec/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
United Therapeutics USD 3.1M 100K Dec/2025